Loading...
Market
What will be Sanofi's tolebrutinib market share in treating non-relapsing secondary progressive MS by June 30, 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Market research reports and pharmaceutical sales data
Story
Sanofi's Tolebrutinib Delays Progressive MS Disability by 31%
Sep 20, 2024, 09:40 AM
Sanofi has announced that its experimental drug, tolebrutinib, has shown promising results in delaying the progression of disability in patients with non-relapsing secondary progressive multiple sclerosis. According to data from a phase 3 trial, tolebrutinib delayed the worsening of the disease by 31%. This development provides hope for patients who currently have no effective treatment options. Sanofi's data indicates a significant 31% delay in disability progression onset.
View original story
Similar markets
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Significantly better • 25%
Moderately better • 25%
Similar • 25%
Worse • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%